drugset / Trial / NCT05872841
H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
NaSingle-groupOpen-labelTreatment
Summary
This study is the first to compare the efficacy and safety of recombinant human adenovirus type 5 injection via hepatic artery infusion combined with TACE-based combination therapy for the treatment of patients with stage IIIa primary hepatocellular carcinoma with portal vein carcinoma thrombosis, providing a safe and reliable treatment method for the clinical treatment of this group of patients, and also providing a reference and basis for the treatment of other tumors with this new treatment model.
Timeline
- Start
- 2023-06-01
- Primary completion
- 2024-12-31
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | H101 | Other / unclassified | 1e+12 unknown | Other |
| Subject | H101 | Other / unclassified | 1.5e+12 unknown | Other |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | calcium folinic acid | Unknown | 400 mg/m2 | — |
| Background | fluorouracil | Small molecule | 1200 mg/m2 | — |